

★ SEAL OF ★
EXCELLENCE



*Certificate delivered by the European Commission,
as the institution managing Horizon 2020,
the EU Framework Programme for Research and Innovation 2014-2020*

The project proposal **696678, ADMIT**

Advanced Disease Modifying Injectable Treatment for Osteoarthritis (OA)

Submitted under the Horizon 2020's **SME instrument phase 2**
call **H2020-SMEInst-2014-2015 (H2020-SMEINST-2-2015)** of **17 June 2015**
in the area of

**SME boosting biotechnology-based industrial
processes driving competitiveness and sustainability**

by

QUALIA PHARMA EMPORIA FARMAKON ANONYMI ETAIREIA

KALABRYTON 2
14564 KIFISIA
Greece

following evaluation by an international panel of independent experts

**WAS SUCCESSFUL IN A HIGHLY COMPETITIVE EVALUATION PROCESS*
AS AN INNOVATIVE PROJECT PROPOSAL**


This proposal is recommended for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

* This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria (excellence, impact, quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020.

Corina Crețu,
Commissioner for
Regional Policy

Carlos Moedas,
Commissioner for Research,
Science and Innovation

Brussels, 01/02/2016



This document is digitally sealed. The digital sealing mechanism uniquely binds the document to the modules of the Participant Portal of the European Commission, to the transaction for which it was generated and ensures its integrity and authenticity.

Any attempt to modify the content will lead to a breach of the electronic seal, which can be verified at any time by clicking on the digital seal validation symbol.